Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Company Overview

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety.

Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.

Key Stats

• Today's Range: $0.41 to $0.46
• 50-Day Range: $0.25 to $0.52
• 52-Week Range: $0.23 to $2.75
• Volume: 530,336 shs
• Average Volume: 3.18 million shs
• Market Capitalization: $8.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Ensysce Biosciences Stock Analysis - MarketRank™

Ensysce Biosciences scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Ensysce Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ensysce Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.09) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ensysce Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ensysce Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.03% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently increased by 496.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ensysce Biosciences does not currently pay a dividend.

Dividend Growth

Ensysce Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

2 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $196,000.00 in company stock, which represents 2.2102% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Ensysce Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $196,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.80% of the stock of Ensysce Biosciences is held by insiders.

Percentage Held by Institutions

5.63% of the stock of Ensysce Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/05/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ENSC
• CIK: 1716947
• Web: ensysce.com
• Phone: 858-263-4196
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.18 million
• Net Margins: -280.53%
• Pretax Margin: -280.51%
• Return on Equity: -2,550.30%
• Return on Assets: -320.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.70
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -7.60

Miscellaneous

• Outstanding Shares: 19,457,000
• Free Float: 18,912,000
• Market Cap: $8.87 million
• Optionable: Not Optionable
• Beta: 0.97